INTRODUCTION
The increase in the cumulative incidence of COVID-19 cases was
accompanied by a gradual increase in reported pediatric
cases.1 However, the clinical course of COVID-19 in
pediatric patients with aplastic anemia (AA) has not been thoroughly
investigated. As of May 2021, only one pediatric and eight adult cases
of COVID-19 in patients with AA have been reported. Some patients
exhibited mild and transient symptoms, while others suffered from severe
manifestations with fatal outcomes.2-6 Data on the
ability of these patients to produce antibodies against the virus under
insufficient immune function are also limited.
We report our experience with COVID-19 in a patient with AA receiving
immunosuppressive therapy (IST) and the dynamic results of the
serological assay. We analyzed the change in immunoglobulin G (IgG),
immunoglobulin M (IgM), and immunoglobulin A (IgA) titers against three
different proteins of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2): S1 subunit of spike protein (S1); receptor-binding domain
(RBD) within the S1 subunit, which is a major target of anti-SARS-CoV-2
neutralizing antibodies7-9; and nucleocapsid protein
(N).